Device type · LCP
Assay, Glycosylated Hemoglobin
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
LCP
Hematology
Device class
Class II
FDA decisions since 2015
20
510(k), De Novo and PMA
Adverse event reports
94
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Assay, Glycosylated Hemoglobin
- Product code
- LCP
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7470
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LCP
Latest FDA decisions
The 8 newest of 20 since 2015.
K221326 · Decided Nov 22, 2024 · 931 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
- Q-Pad Test System510(k)
K231465 · Decided Dec 6, 2023 · 201 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
Abbott Diagnostics Technologies AS
K214117 · Decided Sep 27, 2023 · 636 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
K192987 · Decided Mar 26, 2020 · 153 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
K192369 · Decided Oct 29, 2019 · 60 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
- OneDraw A1C Test System510(k)
K183230 · Decided Aug 15, 2019 · 268 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
K181915 · Decided Apr 12, 2019 · 269 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
- Quo-Test A1c System510(k)
K180509 · Decided Feb 16, 2019 · 354 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
Reports received
94
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
94
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2 | 0 | 0 | 0 |
| Jan 24 | 2 | 0 | 0 | 0 |
| Feb 24 | 5 | 0 | 0 | 0 |
| Mar 24 | 5 | 0 | 0 | 0 |
| Apr 24 | 5 | 0 | 0 | 0 |
| May 24 | 4 | 0 | 0 | 0 |
| Jun 24 | 2 | 0 | 0 | 0 |
| Jul 24 | 3 | 0 | 0 | 0 |
| Aug 24 | 2 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 2 | 0 | 0 | 0 |
| Nov 24 | 5 | 0 | 0 | 0 |
| Dec 24 | 3 | 0 | 0 | 0 |
| Jan 25 | 1 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 2 | 0 | 0 | 0 |
| Apr 25 | 3 | 0 | 0 | 0 |
| May 25 | 7 | 0 | 0 | 0 |
| Jun 25 | 2 | 0 | 0 | 0 |
| Jul 25 | 2 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 2 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 2 | 0 | 0 | 0 |
| Jan 26 | 31 | 0 | 0 | 0 |
| Feb 26 | 9 | 0 | 0 | 0 |
| Mar 26 | 3 | 0 | 0 | 0 |
| Apr 26 | 3 | 0 | 0 | 0 |
| May 26 | 5 | 0 | 0 | 0 |
| Jun 26 | 6 | 0 | 0 | 0 |
| Jul 26 | 7 | 0 | 0 | 0 |
| Aug 26 | 9 | 0 | 0 | 0 |
| Sep 26 | 11 | 0 | 0 | 0 |
| Oct 26 | 8 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Abbott25
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results34
- Low Test Results28
- Computer Software Problem25
- Therapeutic or Diagnostic Output Failure25
- Non Reproducible Results4
- Incorrect Measurement2
- Incorrect, Inadequate or Imprecise Result or Readings2
- Inaccurate Information1
- Insufficient Device Problem Information1
- Output Problem1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions69
- Needle Stick/Puncture25
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Diabetes HbA1c TestOpen, Classified
Z-0732-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
Mckesson Medical-Surgical Inc. Corporate Office
Z-1830-2025 · Started Apr 24, 2025 · Posted by FDA May 27, 2025
Reason given: transit delays of certain cold chain products due to severe thunderstorms which may caused the products to be stored outside the recommended labeled storage conditions. This failure could increase the probability of an incorrect test result or a delayed test result.
Cause as FDA categorized it: Storage
Polymer Technology Systems, Inc. dba PTS Diagnostics, Inc.
Z-0223-2025 · Started Sep 18, 2024 · Posted by FDA Oct 24, 2024
Reason given: The reason for this recall is PTS Diagnostics, Inc. received complaints of non-matching cartridge and analyzer codes within the product test system box. Use of cartridges and analyzers with non-matching codes may result in inaccurate test results as components within each lot number are meant to be used together, and...
Cause as FDA categorized it: Under Investigation by firm
- Afinion 2 Analyzer, model #1116986, US refurbished, CLIA waived.Open, Classified
Abbott Diagnostics Technologies AS
Z-2736-2024 · Started Jun 17, 2024 · Posted by FDA Aug 27, 2024
Reason given: Five Afinion 2 (AF2) Analyzer were incorrectly market configured as Moderate Complexity and distributed to customers. Use of moderately complex assays by waived laboratories could result in erroneous results.
Cause as FDA categorized it: Reprocessing Controls
- DCA Systems HbA1c Reagent KitOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1304-2024 · Started Feb 7, 2024 · Posted by FDA Mar 19, 2024
Reason given: The reason for the recall is that the Siemens DCA HbA1c Reagent Kit was confirmed to display a positive bias without alerting the user. The potential impact of the defect is that erroneous test results could be reported and potentially lead to incorrect patient management of glucose control. A positive bias may be...
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc.
Z-0930-2022 · Started Feb 9, 2022
Reason given: Siemens Healthcare Diagnostics Inc. has confirmed the potential for reagent carryover impacting quality control (QC), patient samples, and calibrator results.
Cause as FDA categorized it: Device Design
Siemens Healthcare Diagnostics, Inc.
Z-2747-2020 · Started Jun 30, 2020
Reason given: If DCA Vantage Analyzer is configured to run Code 39 with check digit, the scanner is not confirming the integrity of read barcode data using the check digit. Also, if DCA Vantage Analyzer is configured to run Code 39 with check digit and an operator erroneously scans a Code 39 barcode without a check digit, the...
Cause as FDA categorized it: Labeling design
Siemens Healthcare Diagnostics, Inc.
Z-2280-2020 · Started May 4, 2020 · Posted by FDA Jun 5, 2020
Reason given: The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples.
Cause as FDA categorized it: Device Design
Showing the 8 newest of 103 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.